GRAL Stock Chart & Stats
$1325.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1325.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$635.65 - $1,997.99
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$58.37B
Enterprise Value$2.17K
Total Cash (Recent Filing)$861.61M
Total Debt (Recent Filing)$91.31M
Price to Earnings (P/E)―
Beta2.77
Next Earnings
Nov 18, 2026EPS Estimate
-42.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.75
Shares Outstanding44,666,233
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,262.04Price Target Upside-4.75% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-169.69
Revenue Forecast (FY)$3.06B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Test-volume GrowthRapid growth in both tests and revenue indicates expanding adoption of Galleri and improving commercial reach. If sustained, higher volume can increase operating leverage, deepen provider relationships, and support a more durable revenue base as the company scales.
Differentiated Clinical PerformanceThe reported clinical evidence supports a meaningful product distinction in a developing early-detection market. Low false positives and strong predictive values can improve physician confidence, support adoption, and strengthen GRAIL’s case for broader access over time.
Low Leverage And Substantial Cash ResourcesA relatively low-debt balance sheet and substantial cash position provide flexibility to fund clinical, regulatory, and commercial initiatives. The Samsung investment also adds strategic support while GRAIL works toward greater scale and potential international expansion.
Bears Say
Large Losses And Continued Cash BurnGRAIL remains far from sustainable profitability despite revenue growth. Negative gross profit, very large operating losses, and substantial cash burn require continued use of its resources or external funding, limiting financial flexibility until unit economics improve materially.
NHS-Galleri Primary Endpoint MissFailure to meet the study’s primary endpoint weakens the clinical evidence package even though secondary findings were positive. That setback may complicate discussions with regulators, healthcare systems, and payers, potentially slowing broader adoption and reimbursement progress.
Regulatory Approval Timing Remains UncertainThe company’s expansion and potential reimbursement pathway depend partly on regulatory progress, yet the advisory committee schedule remains uncertain. Delays would extend the period of commercial investment without approval-related acceleration and could postpone broader market access.
GRAIL Inc News
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $635.65 and its highest was $1997.99 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $58.37B.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is Nov 18, 2026 which is in 64 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Aug 05, 2026. The company reported -$43.295 earnings per share for the quarter, beating the consensus estimate of -$44.919 by $1.624.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Overvalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate is -42.42.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 44,666,233 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$43.295 in its last earnings report, beating expectations of -$44.919. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in MX:GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,262.04 (-4.75% Downside)
$1,262.04 (-4.75% Downside)
Blogger Sentiment
Bullish
MX:GRAL Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $18.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GRAIL Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive commercial and clinical momentum: strong year-over-year revenue and volume growth, meaningful gross profit improvement, substantial cash including a $110M Samsung strategic investment, and a robust, differentiated clinical evidence base with low false positive rate and high PPV. Key execution items — a completed PMA submission, anticipated FDA advisory committee and sales force expansion — support the company’s pathway to broader access. Offsetting these positives are continued large operating losses and a widened adjusted EBITDA shortfall, the NHS primary endpoint miss, pricing/ASP pressure from channel mix and competitive noise, and timing uncertainty around the FDA advisory committee and U.K. decision-making. Taken together, the highlights (growth, cash runway, unique clinical validation and commercialization readiness) outweigh the lowlights, though execution and regulatory timing risks remain significant.View all MX:GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$1,262.04
▼(-4.75% Downside)